Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Hormone Therapy
  •  Head and Neck Oncology
  •  Endometrial Cancer
  •  Carcinomas
  •  Hematology
  •  Blood Cancer
  •  Thoracic Oncology
  •  Endoscopy Methods

Abstract

Citation: Clin Oncol. 2021;6(1):1831.DOI: 10.25107/2474-1663.1831

Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation

Parul D Agarwal* and Michael R Lucey

Department of Medicine, Division of Gastroenterology and Hepatology, University of Wisconsin School of Medicine and Public Health, Madison, USA

*Correspondance to: Parul D Agarwal 

 PDF  Full Text Review Article | Open Access

Abstract:

Despite careful selection for Liver Transplantation (LT) of patients with Hepatocellular Carcinoma (HCC), HCC may still recur after LT and is frequently associated with dismal outcome. Tumor factors, including serum Alpha-Fetoprotein (AFP), the presence of microvascular invasion, tumor grade/differentiation, and largest tumor size are amongst the most important predictors of 
recurrence after transplantation. The nature of recurrence can be highly variable, but often presents with extra-hepatic involvement. As such, management of patients with HCC can be challenging, and consensus guidelines are lacking. Curative options, with surgery or ablation, which may be applicable in patients with isolated intra- or extra-hepatic metastases, offers the best chance for improved long-term outcome in patients with HCC recurrence after transplantation. Most patients with recurrence have unresectable disease, and may benefit from palliative treatments, including intra-arterial therapies and/or systemic therapy.

Keywords:

Alpha fetoprotein; Ablation; Trans-arterial chemoembolization; Chemotherapy

Cite the Article:

Agarwal PD, Lucey MR. Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. Clin Oncol. 2021;6:1831..

Search Our Journal

Journal Indexed In

Articles in PubMed

LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
 PubMed  PMC  PDF  Full Text
NMR Metabolomics in Ionizing Radiation
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Is There Re-Staging Surgery Necessity for Women with Borderline Ovarian Tumors
 Abstract  PDF  Full Text
Expression of the Oncoprotein E5 from Human papillomavirus and miR-203 in Pre-Cancer Lesions and Cervical Cancer
 Abstract  PDF  Full Text
View More...